Paul Jeng
Stock Analyst at Guggenheim
(2.91)
# 1,659
Out of 5,067 analysts
6
Total ratings
100%
Success rate
29.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Initiates: Buy | $9 | $1.80 | +400.00% | 1 | Nov 24, 2025 | |
| IMTX Immatics | Maintains: Buy | $16 → $19 | $10.20 | +86.27% | 2 | Nov 18, 2025 | |
| IMCR Immunocore Holdings | Assumes: Neutral | n/a | $39.35 | - | 1 | Sep 18, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $5 | $1.09 | +358.72% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $33.99 | +47.10% | 1 | Sep 18, 2025 |
Adagene
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $1.80
Upside: +400.00%
Immatics
Nov 18, 2025
Maintains: Buy
Price Target: $16 → $19
Current: $10.20
Upside: +86.27%
Immunocore Holdings
Sep 18, 2025
Assumes: Neutral
Price Target: n/a
Current: $39.35
Upside: -
Context Therapeutics
Sep 18, 2025
Initiates: Buy
Price Target: $5
Current: $1.09
Upside: +358.72%
IDEAYA Biosciences
Sep 18, 2025
Initiates: Buy
Price Target: $50
Current: $33.99
Upside: +47.10%